Upper-airway cough syndrome adverse event reports that record this term

Kind of term: MedDRA preferred term

What a report is

A report is not proof that the drug was the cause of the event.

FDA says:

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview, section "Responsible use of the data". The site read the page on 2 Oct 2026. The data have the reports that FDA received through 30 Jun 2026.

FDA also says:

There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event. The information in these reports has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of these events.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.
Source: openFDA, Response of the drug event API (meta.disclaimer). The site read the page on 2 Oct 2026.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

Reports on file

From July 2004 to June 2026, FDA received 8,087 adverse event reports that record the MedDRA preferred term Upper-airway cough syndrome. The person who codes a report selects the term that agrees best with the description of the reporter.

FDA received 575 reports in the 12 months to June 2026 and 576 in the 12 months before. FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

By reports in the 12 months to June 2026, this term was number 912 of 1,436 reaction terms with a page. Of the 1,332,454 drug reports that FDA received in the 12 months to June 2026, 575 (under 0.1%) record this term. Reports for female patients were 67.3% of the reports that record this term and 52.7% of all drug reports.

The number of people who use the product is not in the data. A count is not a rate.

MedDRA

The Medical Dictionary for Regulatory Activities. The person who codes a report selects the preferred term that agrees best with the description of the reporter. FDA does not publish the description.

Data version

openFDA FAERS release of 29 Oct 2026. Reports received through 30 Jun 2026.

Drugs in these reports

The table has the 138 drug pages with 25 or more reports that record this term. The rows are in order of name. A drug page with fewer reports for this term is not in the table. The counts are the counts that the site keeps for each reaction term, and a count can be lower than the count of FDA.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Drugs that the reports with the term Upper-airway cough syndrome name as a suspect product, in order of name
Drug	Class	Reports with this term
Acetaminophen		87
Aclidinium bromide	Anticholinergic	35
Actemra	Interleukin-6 receptor antagonist	71
Advair Diskus	Corticosteroid	26
Advair Hfa	Corticosteroid	104
Albuterol	beta2-Adrenergic agonist	381
Albuterol sulfate	beta2-Adrenergic agonist	269
Alendronate sodium	Bisphosphonate	115
Allegra		30
Alvesco		92
Ambrisentan	Endothelin receptor antagonist	39
Amlodipine	Calcium channel blocker	59
Amlodipine besylate	Dihydropyridine calcium channel blocker	41
Amoxicillin	Penicillin-class antibacterial	25
Amoxicillin trihydrate		38
Aredia		37
Aspirin	Nonsteroidal anti-inflammatory drug	48
Azithromycin	Macrolide antimicrobial	169
Azithromycin Anhydrous		68
Bactrim	Dihydrofolate reductase inhibitor antibacterial	28
Bisoprolol	beta-Adrenergic blocker	99
Breo Ellipta	Corticosteroid	123
Budesonide	Corticosteroid	193
Budesonide Formoterol		26
Budesonide Formoterol Fumarate		160
Calcium carbonate	Blood coagulation factor	78
Cannabis Sativa Flowering Top		30
Ceftriaxone	Cephalosporin antibacterial	26
Ceftriaxone sodium	Cephalosporin antibacterial	158
Ciprofloxacin	Fluoroquinolone antibacterial	33
Citalopram	Serotonin reuptake inhibitor	33
Clarispray Nasal Allergy		207
Cosentyx	Interleukin-17A antagonist	102
Cyclophosphamide	Alkylating drug	26
Cymbalta		26
Diazepam	Benzodiazepine	102
Domperidone		26
Dupilumab	Interleukin-4 receptor alpha antagonist	34
Dupixent	Interleukin-4 receptor alpha antagonist	668
Enbrel	Tumor necrosis factor blocker	409
Entresto	Angiotensin 2 receptor blocker	73
Esbriet	Pyridone	44
Escitalopram oxalate	Serotonin reuptake inhibitor	94
Ferrous gluconate		96
Flonase	Corticosteroid	39
Flovent	Corticosteroid	37
Fluticasone propionate	Corticosteroid	51
Fosamax	Bisphosphonate	86
Furosemide	Loop diuretic	100
Gabapentin	Anti-epileptic agent	39
Gilenya	Sphingosine 1-phosphate receptor modulator	27
Human immunoglobulin g	Human immunoglobulin G	50
Humira		428
Humira 40 Mg/0 8 Ml Pen		38
Hydrochlorothiazide	Thiazide diuretic	37
Ibrance	Kinase inhibitor	66
Imbruvica	Kinase inhibitor	38
Ipratropium bromide	Anticholinergic	154
Iron		36
Jakafi	Janus kinase inhibitor	29
Kesimpta	CD20-directed cytolytic antibody	30
Lasix	Loop diuretic	57
Levothyroxine		26
Levothyroxine sodium	l-Thyroxine	46
Lisinopril	Angiotensin converting enzyme inhibitor	50
Meloxicam	Nonsteroidal anti-inflammatory drug	102
Mepolizumab	Interleukin-5 antagonist	259
Metformin	Biguanide	28
Methotrexate	Folate analog metabolic inhibitor	94
Methylprednisolone sodium succinate	Corticosteroid	28
Montelukast	Leukotriene receptor antagonist	35
Montelukast sodium	Leukotriene receptor antagonist	45
Nasacort Allergy 24HR	Corticosteroid	27
Nasonex	Corticosteroid	41
Nexium	Proton pump inhibitor	53
Nicoderm Cq	Cholinergic nicotinic agonist	39
Niraparib	Poly(ADP-Ribose) polymerase inhibitor	25
Nucala	Interleukin-5 antagonist	314
Ocrevus	CD20-directed cytolytic antibody	29
Ofev	Kinase inhibitor	60
Olanzapine	Atypical antipsychotic	29
Omalizumab	Anti-IgE	378
Omeprazole	Proton pump inhibitor	34
Omnaris		51
Opsumit	Endothelin receptor antagonist	69
Otezla	Phosphodiesterase 4 inhibitor	49
Pantoprazole	Proton pump inhibitor	51
Paxlovid		83
Perindopril		28
Pomalyst	Thalidomide analog	26
Prednisolone	Corticosteroid	25
Prednisone	Corticosteroid	541
Prolia	RANK ligand inhibitor	41
Pulmicort Turbuhaler		367
Rabeprazole	Proton pump inhibitor	53
Rabeprazole sodium	Proton pump inhibitor	73
Remicade	Tumor necrosis factor blocker	38
Remodulin	Prostacycline vasodilator	27
Repatha	PCSK9 inhibitor	188
Restasis	Calcineurin inhibitor immunosuppressant	36
Revlimid	Thalidomide analog	168
Rinvoq	Janus kinase inhibitor	42
Rituxan	CD20-directed cytolytic antibody	40
Rituximab	CD20-directed cytolytic antibody	71
Rosuvastatin calcium	HMG-CoA reductase inhibitor	102
Rupatadine		151
Rupatadine Fumarate		156
Salbutamol		108
Salbutamol sulfate		54
Singulair	Leukotriene receptor antagonist	425
Skyrizi	Interleukin-23 antagonist	34
Spiriva Respimat	Anticholinergic	34
Spironolactone	Aldosterone antagonist	94
Symbicort	Corticosteroid	326
Synthroid	l-Thyroxine	109
Tamiflu	Neuraminidase inhibitor	180
Tecfidera		38
Tiotropium		102
Tiotropium bromide	Anticholinergic	278
Tiotropium bromide monohydrate		47
Topiramate		34
Trichlormethiazide		100
Trikafta		30
Tums	Blood coagulation factor	28
Tylenol	Expectorant	69
Tysabri	Integrin receptor antagonist	48
Tyvaso	Prostacycline vasodilator	71
Tyvaso DPI	Prostacycline vasodilator	52
Umeclidinium bromide		57
Uptravi	Prostacyclin receptor agonist	30
Ventolin Hfa	beta2-Adrenergic agonist	37
Xeljanz	Janus kinase inhibitor	97
Xiidra		45
Xolair	Anti-IgE	204
Xyrem	Central nervous system depressant	76
Zejula	Poly(ADP-Ribose) polymerase inhibitor	39
Zenhale		87
Zometa		55

The page of each drug has the count of each reaction term in its reaction lookup.

Drug classes in these reports

The table has the 47 pharmacologic classes with 50 or more reports that record this term. The rows are in order of name.

FDA says:

Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

Importantly, the AEMS data by themselves are not an indicator of the safety profile of the drug or biologic.
Source: FDA, FDA Adverse Event Monitoring System (AEMS) Public Dashboard. Content current as of 11 Mar 2026. The site read the page on 2 Oct 2026.

Pharmacologic classes of the drugs that the reports with the term Upper-airway cough syndrome name, in order of name
Class	Reports with this term
Aldosterone antagonist	94
Angiotensin 2 receptor blocker	113
Angiotensin converting enzyme inhibitor	68
Anti-epileptic agent	53
Anti-IgE	584
Anticholinergic	570
Atypical antipsychotic	68
Benzodiazepine	133
beta-Adrenergic blocker	134
beta2-Adrenergic agonist	708
Bisphosphonate	221
Blood coagulation factor	106
Calcium channel blocker	59
CD20-directed cytolytic antibody	170
Central nervous system depressant	94
Cephalosporin antibacterial	188
Corticosteroid	1,749
Endothelin receptor antagonist	145
Expectorant	75
Folate analog metabolic inhibitor	118
GLP-1 receptor agonist	64
Histamine-1 receptor antagonist	63
HMG-CoA reductase inhibitor	136
Human immunoglobulin G	72
Integrin receptor antagonist	77
Interleukin-17A antagonist	108
Interleukin-4 receptor alpha antagonist	702
Interleukin-5 antagonist	573
Interleukin-6 receptor antagonist	77
Janus kinase inhibitor	170
Kinase inhibitor	250
l-Thyroxine	155
Leukotriene receptor antagonist	505
Loop diuretic	157
Macrolide antimicrobial	171
Neuraminidase inhibitor	180
Nonsteroidal anti-inflammatory drug	188
Opioid agonist	61
PCSK9 inhibitor	210
Phosphodiesterase 4 inhibitor	51
Poly(ADP-Ribose) polymerase inhibitor	77
Prostacycline vasodilator	196
Proton pump inhibitor	326
Pyridone	51
Serotonin reuptake inhibitor	175
Thalidomide analog	200
Tumor necrosis factor blocker	507

A class with many reports in all has many reports for almost every term.

Reports by month

Reports that record Upper-airway cough syndrome, by month, five years to June 2026

FDA releases FAERS data every quarter, so the newest months are not complete. They grow in later releases.

Patients in these reports

Age of the patient in the reports that record Upper-airway cough syndrome
Age	Reports	Share
Under 2	3	under 0.1%
2 to 11	27	0.3%
12 to 17	56	0.7%
18 to 44	1,038	12.8%
45 to 64	2,417	29.9%
65 to 74	1,120	13.8%
75 and over	779	9.6%
Age not given	2,647	32.7%

Sex of the patient in the reports that record Upper-airway cough syndrome
Sex	Reports	Share
Female	5,444	67.3%
Male	2,066	25.5%
Unknown or not given	577	7.1%

Age and sex are as the report gives them. 81.4% of these reports give the United States as the country.

Terms near this one

These are the next terms in the A to Z list. The links are for navigation.

Official pages

MedWatch Online Voluntary Reporting FormThe online form of FDA for a voluntary report.
MedWatch: The FDA Safety Information and Adverse Event Reporting ProgramThe page of the FDA program that receives reports about drugs and devices.
FDA Adverse Event Monitoring System (AEMS) Public DashboardThe public dashboard of FDA for adverse event reports on drugs and biologics.

The site checked these addresses on 2 Oct 2026. The links open in a new tab.

Cite this page

Reported Reactions. Upper-airway cough syndrome: adverse event reports that record this term. https://reportedreactions.com/reaction/upper-airway-cough-syndrome/ Source: U.S. Food and Drug Administration, openFDA Drug Adverse Event (FAERS) files, release of 29 Oct 2026. Reports received through 30 Jun 2026.

Where the data come from

The counts come from the openFDA Drug Adverse Event (FAERS) bulk files, release of 29 Oct 2026. The files have the reports that FDA received through 30 Jun 2026. A drug name is the name on the report. The site matches it to a brand name or a generic name of the National Drug Code Directory of 2 Nov 2026. A class is the pharmacologic class (EPC) of the FDA label.

The count has the reports with each spelling of one MedDRA preferred term. The site does not publish a report narrative, a lot number, a detail of a patient or the identity of a reporter. The record of FDA is the authority. See how the site counts reports, the data sources and the corrections page.

Questions

What does Upper-airway cough syndrome mean in an adverse event report?

It is a MedDRA preferred term. FDA codes the description of a reporter with the MedDRA dictionary. The openFDA files do not have the description itself, and this site does not show it.

Does a drug in the table mean that the drug was responsible for this reaction?

No. FDA says:

No individual drug is connected to any individual reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

When a report lists multiple drugs and multiple reactions, there is no way to conclude from the data therein that a given drug is responsible for a given reaction.
Source: openFDA, Drug Adverse Event Overview. The site read the page on 2 Oct 2026.

What does this page tell a person who has this symptom?

This page gives counts of reports. It cannot assess a person. A pharmacist or a clinician can assess a person.

If this is a medical emergency, please call 911.
Source: FDA, MedWatch Online Voluntary Reporting Form. The site read the page on 2 Oct 2026.

To the top of the page